Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Rev Med Chil ; 145(1): 115-120, 2017 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-28393977

RESUMO

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that most commonly manifests as cutaneous lesions with or without bone marrow involvement and leukemic dissemination. The demonstration of tumor cells with the characteristic immunophenotype with expression of CD56, generally CD4 and dendritic cell antigens (CD123, cyTCL-1, HLA-DR), in the absence of myeloid or lymphoid lineage markers is required for the diagnosis. Responses to chemotherapy are initially satisfactory, with frequent systemic and central nervous system relapses. We report a 24 year-old male with BPDCN, initially diagnosed and treated as non-Hodgkin CD4+ T-cell lymphoma, with initial complete remission who evolved with early central nervous system relapse. A second attempt of chemotherapy failed and the patient died two months later.


Assuntos
Neoplasias do Sistema Nervoso Central/secundário , Células Dendríticas/patologia , Neoplasias Hematológicas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Progressão da Doença , Evolução Fatal , Neoplasias Hematológicas/tratamento farmacológico , Humanos , Imunofenotipagem , Masculino , Indução de Remissão , Adulto Jovem
2.
Rev. méd. Chile ; 145(1): 115-120, ene. 2017. ilus, graf, tab
Artigo em Espanhol | LILACS | ID: biblio-845510

RESUMO

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that most commonly manifests as cutaneous lesions with or without bone marrow involvement and leukemic dissemination. The demonstration of tumor cells with the characteristic immunophenotype with expression of CD56, generally CD4 and dendritic cell antigens (CD123, cyTCL-1, HLA-DR), in the absence of myeloid or lymphoid lineage markers is required for the diagnosis. Responses to chemotherapy are initially satisfactory, with frequent systemic and central nervous system relapses. We report a 24 year-old male with BPDCN, initially diagnosed and treated as non-Hodgkin CD4+ T-cell lymphoma, with initial complete remission who evolved with early central nervous system relapse. A second attempt of chemotherapy failed and the patient died two months later.


Assuntos
Humanos , Masculino , Adulto Jovem , Células Dendríticas/patologia , Neoplasias do Sistema Nervoso Central/secundário , Neoplasias Hematológicas/patologia , Indução de Remissão , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Imunofenotipagem , Evolução Fatal , Progressão da Doença , Neoplasias Hematológicas/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA